Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Leases (2022 - 2025)

Dianthus Therapeutics has reported Current Leases over the past 4 years, most recently at $217000.0 for Q3 2025.

  • Quarterly results put Current Leases at $217000.0 for Q3 2025, down 30.23% from a year ago — trailing twelve months through Sep 2025 was $217000.0 (down 30.23% YoY), and the annual figure for FY2024 was $320000.0, down 23.26%.
  • Current Leases for Q3 2025 was $217000.0 at Dianthus Therapeutics, up from $211000.0 in the prior quarter.
  • Over the last five years, Current Leases for DNTH hit a ceiling of $3.6 million in Q3 2022 and a floor of $211000.0 in Q2 2025.
  • Median Current Leases over the past 4 years was $377000.0 (2024), compared with a mean of $1.0 million.
  • Peak annual rise in Current Leases hit 19.14% in 2023, while the deepest fall reached 88.59% in 2023.
  • Dianthus Therapeutics' Current Leases stood at $350000.0 in 2022, then increased by 19.14% to $417000.0 in 2023, then dropped by 23.26% to $320000.0 in 2024, then tumbled by 32.19% to $217000.0 in 2025.
  • The last three reported values for Current Leases were $217000.0 (Q3 2025), $211000.0 (Q2 2025), and $226000.0 (Q1 2025) per Business Quant data.